Global Systematic Fungal Infection Therapeutics Market Size, by Drug Type (Echinocandins, Azoles), by Therapeutic Indications (Aspergillosis, Dermatophytosis), by Dosage Form, & Region - Key Manufacturers, Analysis, Growth Trends, and Forecast till 2026

  • Category : Healthcare and Pharma
  • |
  • ID : 1332039
  • |
  • Date : October 2019
  • |
  • No of Pages: 121
  • |
  • Publisher : Intellectual Research Partners

The fungal infection in the body is caused due to unhygienic and unclean environments wherein fungal agent thrive. These agents multiply by spreading spores that subsequently lead to infection on skin (superficial) or when inhaled (systemic)-fungal infections. These infections are mostly non-lethal, but can result in death in rare cases.

The global systematic fungal infection therapeutics market was estimated to be valued at USD XX million in 2018 and is projected to reach USD XX million by 2026, at a CAGR of XX% during 2019 to 2026. Increase in the prevalence of fungal infections such as aspergillosis and candidiasis, patients suffering from hospital-acquired infections are factors supplementing the market growth globally. Additionally, continuous development of new generic as well as innovative anti-infective drugs and formulation technologies to combat serious fungal infections drive the market growth. However, presence of counterfeit drugs and resistance toward antifungal drugs are some of the major factors impeding the growth of the market.

The global systematic fungal infection therapeutics market is primarily segmented based on different drug type, therapeutic indications, dosage forms, and geography. Based on drug type, it is classified into echinocandins, azoles, polyenes, allylamines. Furthermore, based on therapeutic indications the market is categorized into aspergillosis, dermatophytosis, candidiasis, and others. In terms of dosage forms, it is divided into powders, ointments, drugs, and pastes. Region wise, it is analyzed across North America, Europe, Asia-Pacific, South America, and MEA.

On the basis of drug type, the market is split into:
* Echinocandins
* Azoles
* Polyenes
* Allylamines

On the basis of therapeutic indications, the market is split into:
* Aspergillosis
* Dermatophytosis
* Candidiasis
* Other Indications

On the basis of dosage form, the market is split into:
* Powders
* Ointments
* Drugs
* Others

Moreover, the market is classified based on regions and countries as follows:
* North America- U.S., Canada
* Europe- U.K., France, Germany, Italy and Rest of Europe
* Asia-Pacific- China, Japan, India and Rest of Asia Pacific
* South America- Brazil, Mexico and Rest of South America
* Middle East & Africa- South Africa, Saudi Arabia and Rest of Middle East & Africa

Key Market Players:
The key players profiled in the market include:
* Pfizer Inc.
* Sanofi S.A.
* Gilead Sciences, Inc.
* Merck & Co., Inc.
* Novartis International AG
* Abbott Laboratories
* Bayer AG
* Scynexis Inc.
* Enzon Pharmaceuticals, Inc.
* GlaxoSmithKline Plc.

These enterprises are focusing on growth strategies, such as new product launches, expansions, acquisitions, and agreements & partnerships to expand their operations across the globe.

Key Benefits of the Report:
* Global, regional, country, drug type, and therapeutic indications market size and their forecast from 2015-2026
* Identification and detailed analysis on key market dynamics, such as, drivers, restraints, opportunities, and challenges influencing growth of the market
* Detailed analysis on industry outlook with market specific PESTLE, and supply chain to better understand the market and build expansion strategies
* Identification of key market players and comprehensively analyze their market share and core competencies, detailed financial positions, key products, and unique selling points
* Analysis on key players’ strategic initiatives and competitive developments, such as joint ventures, mergers, and new product launches in the market
* Expert interviews and their insights on market shift, current and future outlook, and factors impacting vendors’ short term and long term strategies
* Detailed insights on emerging regions, drug type, and therapeutic indications with qualitative and quantitative information and facts

Target Audience:
* Systematic Fungal Infection Drugs Manufacturers
* Traders, Importers, and Exporters
* Raw Material Suppliers and Distributors
* Research and Consulting Firms
* Government and Research Organizations
* Associations and Industry Bodies

Research Methodology:
The market is derived through extensive use of secondary, primary, in-house research followed by expert validation and third party perspective, such as, analyst reports of investment banks. The secondary research is the primary base of our study wherein we conducted extensive data mining, referring to verified data sources, such as, white papers, government and regulatory published articles, technical journals, trade magazines, and paid data sources.

For forecasting, regional demand & supply factors, recent investments, market dynamics including technical growth scenario, consumer behavior, and end use trends and dynamics, and production capacity were taken into consideration. Different weightages have been assigned to these parameters and quantified their market impacts using the weighted average analysis to derive the market growth rate.

The market estimates and forecasts have been verified through exhaustive primary research with the Key Industry Participants (KIPs), which typically include:
* Manufacturers
* Suppliers
* Distributors
* Government Body & Associations
* Research Institutes

TABLE OF CONTENTS

1. Introduction

2. Research Methodology

3. Executive Summary

4. Global Systematic Fungal Infection Therapeutics Market Overview
4.1. Market Segmentation & Scope
4.2. Market Trends
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Supply Chain Analysis
4.3. Global Systematic Fungal Infection Therapeutics Market - Porter\'s Five Forces Analysis
4.4. Global Systematic Fungal Infection Therapeutics Market - PESTEL Analysis

5. Global Systematic Fungal Infection Therapeutics Market, by Drug Type
5.1. Global Systematic Fungal Infection Therapeutics Market, Size and Forecast, 2015-2026
5.2. Global Systematic Fungal Infection Therapeutics Market, by Echinocandins, 2015-2026
5.2.1. Key driving factors, trends and opportunities
5.2.2. Market size and forecast, 2015-2026
5.3. Global Systematic Fungal Infection Therapeutics Market, by Azoles, 2015-2026
5.3.1. Key driving factors, trends and opportunities
5.3.2. Market size and forecast, 2015-2026
5.4. Global Systematic Fungal Infection Therapeutics Market, by Polyenes, 2015-2026
5.4.1. Key driving factors, trends and opportunities
5.4.2. Market size and forecast, 2015-2026
5.5. Global Systematic Fungal Infection Therapeutics Market, by Allylamines, 2015-2026
5.5.1. Key driving factors, trends and opportunities
5.5.2. Market size and forecast, 2015-2026

6. Global Systematic Fungal Infection Therapeutics Market, by Therapeutic Indications
6.1. Global Systematic Fungal Infection Therapeutics Market, Size and Forecast, 2015-2026
6.2. Global Systematic Fungal Infection Therapeutics Market, by Aspergillosis, 2015-2026
6.2.1. Key driving factors, trends and opportunities
6.2.2. Market size and forecast, 2015-2026
6.3. Global Systematic Fungal Infection Therapeutics Market, by Dermatophytosis, 2015-2026
6.3.1. Key driving factors, trends and opportunities
6.3.2. Market size and forecast, 2015-2026
6.4. Global Systematic Fungal Infection Therapeutics Market, by Candidiasis, 2015-2026
6.4.1. Key driving factors, trends and opportunities
6.4.2. Market size and forecast, 2015-2026
6.5. Global Systematic Fungal Infection Therapeutics Market, by Other Indications, 2015-2026
6.5.1. Key driving factors, trends and opportunities
6.5.2. Market size and forecast, 2015-2026

7. Global Systematic Fungal Infection Therapeutics Market, by Dosage Form
7.1. Global Systematic Fungal Infection Therapeutics Market, Size and Forecast, 2015-2026
7.2. Global Systematic Fungal Infection Therapeutics Market, by Powders, 2015-2026
7.2.1. Key driving factors, trends and opportunities
7.2.2. Market size and forecast, 2015-2026
7.3. Global Systematic Fungal Infection Therapeutics Market, by Ointments, 2015-2026
7.3.1. Key driving factors, trends and opportunities
7.3.2. Market size and forecast, 2015-2026
7.4. Global Systematic Fungal Infection Therapeutics Market, by Drugs, 2015-2026
7.4.1. Key driving factors, trends and opportunities
7.4.2. Market size and forecast, 2015-2026
7.5. Global Systematic Fungal Infection Therapeutics Market, by Others, 2015-2026
7.5.1. Key driving factors, trends and opportunities
7.5.2. Market size and forecast, 2015-2026

8. Global Systematic Fungal Infection Therapeutics Market, by Region
8.1. Systematic Fungal Infection Therapeutics Market Regional Analysis, 2015-2026
8.2. Global Systematic Fungal Infection Therapeutics Market Revenue (USD Million) by Region, 2015-2026
8.3. North America Systematic Fungal Infection Therapeutics Market, 2015-2026
8.3.1. North America Systematic Fungal Infection Therapeutics Market Size and Forecast, 2015-2026
8.3.2. North America Systematic Fungal Infection Therapeutics Market by Country, 2015-2026
8.3.2.1. U.S. Systematic Fungal Infection Therapeutics Market, 2015-2026
8.3.2.2. Canada Systematic Fungal Infection Therapeutics Market, 2015-2026
8.4. Europe Systematic Fungal Infection Therapeutics Market, 2015-2026
8.4.1. Europe Systematic Fungal Infection Therapeutics Market Size and Forecast, 2015-2026
8.4.2. Europe Systematic Fungal Infection Therapeutics Market by Country, 2015-2026
8.4.2.1. Germany Systematic Fungal Infection Therapeutics Market, 2015-2026
8.4.2.2. France Systematic Fungal Infection Therapeutics Market, 2015-2026
8.4.2.3. Italy Systematic Fungal Infection Therapeutics Market, 2015-2026
8.4.2.4. UK Systematic Fungal Infection Therapeutics Market, 2015-2026
8.4.2.5. Spain Systematic Fungal Infection Therapeutics Market, 2015-2026
8.4.2.6. Rest of Europe Systematic Fungal Infection Therapeutics Market, 2015-2026
8.5. Asia Pacific Systematic Fungal Infection Therapeutics Market, 2015-2026
8.5.1. Asia Pacific Systematic Fungal Infection Therapeutics Market Size and Forecast, 2015-2026
8.5.2. Asia Pacific Systematic Fungal Infection Therapeutics Market by Country, 2015-2026
8.5.2.1. Japan Systematic Fungal Infection Therapeutics Market, 2015-2026
8.5.2.2. China Systematic Fungal Infection Therapeutics Market, 2015-2026
8.5.2.3. India Systematic Fungal Infection Therapeutics Market, 2015-2026
8.5.2.4. Rest of Asia Pacific Systematic Fungal Infection Therapeutics Market, 2015-2026
8.6. South America Systematic Fungal Infection Therapeutics Market, 2015-2026
8.6.1. South America Systematic Fungal Infection Therapeutics Market Size and Forecast, 2015-2026
8.6.2. South America Systematic Fungal Infection Therapeutics Market by Country, 2015-2026
8.6.2.1. Mexico Systematic Fungal Infection Therapeutics Market, 2015-2026
8.6.2.2. Brazil Systematic Fungal Infection Therapeutics Market, 2015-2026
8.6.2.3. Rest of South America Systematic Fungal Infection Therapeutics Market, 2015-2026
8.7. Middle East & Africa Systematic Fungal Infection Therapeutics Market, 2015-2026
8.7.1. Middle East & Africa Systematic Fungal Infection Therapeutics Market Size and Forecast, 2015-2026
8.7.2. Middle East & Africa Systematic Fungal Infection Therapeutics Market by Country, 2015-2026
8.7.2.1. Saudi Arabia Systematic Fungal Infection Therapeutics Market, 2015-2026
8.7.2.2. South Africa Systematic Fungal Infection Therapeutics Market, 2015-2026
8.7.2.3. Rest of Middle East & Africa Systematic Fungal Infection Therapeutics Market, 2015-2026

9. Competitive Landscape
9.1. Introduction
9.2. Market Share Analysis/Top Player Positioning, 2018

10. Company Profiles
10.1. Pfizer Inc.
10.1.1. Company Overview
10.1.2. Financial Overview
10.1.3. Product Benchmarking
10.1.4. Key Developments
10.2. Sanofi S.A.
10.2.1. Company Overview
10.2.2. Financial Overview
10.2.3. Product Benchmarking
10.2.4. Key Developments
10.3. Gilead Sciences, Inc.
10.3.1. Company Overview
10.3.2. Financial Overview
10.3.3. Product Benchmarking
10.3.4. Key Developments
10.4. Merck & Co., Inc.
10.4.1. Company Overview
10.4.2. Financial Overview
10.4.3. Product Benchmarking
10.4.4. Key Developments
10.5. Novartis International AG
10.5.1. Company Overview
10.5.2. Financial Overview
10.5.3. Product Benchmarking
10.5.4. Key Developments
10.6. Abbott Laboratories
10.6.1. Company Overview
10.6.2. Financial Overview
10.6.3. Product Benchmarking
10.6.4. Key Developments
10.7. Bayer AG
10.7.1. Company Overview
10.7.2. Financial Overview
10.7.3. Product Benchmarking
10.7.4. Key Developments
10.8. Scynexis Inc.
10.8.1. Company Overview
10.8.2. Financial Overview
10.8.3. Product Benchmarking
10.8.4. Key Developments
10.9. Enzon Pharmaceuticals, Inc.
10.9.1. Company Overview
10.9.2. Financial Overview
10.9.3. Product Benchmarking
10.9.4. Key Developments
10.10. GlaxoSmithKline Plc.
10.10.1. Company Overview
10.10.2. Financial Overview
10.10.3. Product Benchmarking
10.10.4. Key Developments

11. Key Insights

Content are not available

Choose License Type